Лучшие больницы для «ICSI Treatment» в Хайдарабад, Индия

A complete ICSI cycle — including controlled ovarian stimulation monitoring, transvaginal egg retrieval, ICSI microinjection procedure, blastocyst-stage embryo culture in a time-lapse incubator, and one fresh embryo transfer — costs approximately $2,500 to $5,500 USD in India (at JCI- and NABH-accredited centers in cities such as Mumbai, Delhi, Chennai, and Hyderabad). The same procedure at JCI- and DHA-accredited centers in Dubai or Abu Dhabi typically ranges from $5,000 to $10,000 USD. India is therefore 40–60% more affordable for equivalent laboratory technology and clinical expertise. Add-on procedures such as PGT-A (Preimplantation Genetic Testing for Aneuploidies) add $1,500–$3,000 USD; micro-TESE for azoospermia adds $1,000–$2,500 USD; ERA (Endometrial Receptivity Analysis) adds $600–$1,200 USD; and blastocyst vitrification and cryo-storage are charged separately at both destinations. GAF Healthcare provides a fully itemized cost estimate in writing before any travel commitment, with no hidden fees.

International patients undergoing a fresh ICSI cycle should plan for a total in-country stay of 2 to 4 weeks. The timeline breaks down as follows: you may begin stimulation injections in your home country and arrive at the partner center around Day 6–8 of stimulation (approximately 1 week before egg retrieval), or arrive from Day 1 for full monitoring. Egg retrieval occurs on approximately Day 10–12 of stimulation. Embryo culture to the blastocyst stage takes 5–6 days. A fresh embryo transfer is performed on Day 5/6 after retrieval. Following transfer, a minimum rest period of 5–7 days is recommended before flying, allowing for the first beta-hCG blood test on Day 10–12 post-transfer. Most physicians advise against long-haul international flights (>4 hours) for at least 10–14 days post-transfer to avoid dehydration, venous thromboembolism risk, and physical stress during the critical early implantation window. Patients at high risk of Ovarian Hyperstimulation Syndrome (OHSS) — typically those with PCOS, high AMH, or a large number of eggs retrieved — may need to stay an additional 7–14 days until symptoms fully resolve, as OHSS is a contraindication to air travel. Frozen embryo transfer (FET) cycles, where all embryos are vitrified and transfer is deferred to a subsequent cycle, require only a 5–7 day in-country stay for the transfer portion. GAF Healthcare builds flexible accommodation and flight bookings for all patients to accommodate these contingencies.

The clinical pregnancy rate (confirmed intrauterine pregnancy on ultrasound) for ICSI at GAF Healthcare partner centers ranges from 40% to 60% per embryo transfer cycle, comparable to the best global IVF programs. Live birth rates — the most meaningful metric — are approximately 35–50% per transfer in women under 35 using their own eggs. These figures decline with advancing maternal age: approximately 30–40% in women aged 35–37, 20–30% in ages 38–40, and 10–15% in women over 40 using own oocytes. For patients using donor eggs (younger, chromosomally tested donors), live birth rates exceed 55–65% per transfer regardless of recipient age. Key factors that improve success rates at partner centers include: (1) Extended culture to the blastocyst stage (Day 5/6) rather than Day 3 cleavage stage — blastocyst transfer increases implantation rates by 15–20%. (2) Time-lapse incubation (EmbryoScope+) with AI-based embryo ranking (KIDScore, iDAScore). (3) PGT-A for euploid blastocyst selection — in women ≥38 or with recurrent implantation failure, transferring a confirmed euploid embryo raises per-transfer live birth rates to 50–65% and reduces miscarriage to <5%. (4) IMSI or PICSI for severe teratozoospermia or elevated sperm DNA fragmentation. (5) ERA testing to identify the personalized window of implantation in recurrent implantation failure cases. Cumulative live birth rates — accounting for all fresh and frozen transfers from one egg retrieval — reach 70–80% over 2–3 cycles in good-prognosis patients under 38. GAF Healthcare's partner centers provide individualized prognosis estimates based on your specific ovarian reserve markers (AMH, AFC), age, sperm parameters, and prior cycle history during your pre-cycle teleconsultation.